Literature DB >> 9880564

Molecular cloning and expression of lipid transfer inhibitor protein reveals its identity with apolipoprotein F.

X Wang1, D M Driscoll, R E Morton.   

Abstract

Published studies demonstrate that lipid transfer inhibitor protein (LTIP) is an important regulator of cholesteryl ester transfer protein (CETP) activity. Although LTIP inhibits CETP activity among different lipoprotein classes, it preferentially suppresses transfer events involving low density lipoprotein (LDL), whereas transfers involving high density lipoprotein as donor are less affected. In this study, we report the purification of LTIP and the expression of its cDNA in cultured cells. Purification of LTIP, in contrast to other published protocols, took advantage of the tight association of this protein with LDL. Ultracentrifugally isolated LDL was further purified on anti-apoE and apoA-I affinity columns. Affinity purified LDL was delipidated by tetramethylurea, and the tetramethylurea-soluble proteins were separated by SDS-polyacrylamide gel electrophoresis. The protein migrating at a molecular mass of approximately 33 kDa was excised from the gel and its N-terminal amino acid sequence determined. The 14-amino acid sequence obtained showed complete homology with the sequence deduced for apolipoprotein F (apoF) cDNA isolated from Hep G2 cells. On Western blots, peptide-specific antibodies raised against synthetic fragments of apoF reacted with the same 33-kDa protein in LTIP-containing fractions purified from LDL and from lipoprotein-deficient plasma. In contrast to that previously reported, apoF was shown to be associated almost exclusively with LDL, identical to the distribution of LTIP activity. The cDNA for apoF was cloned from a human liver cDNA library, ligated into a mammalian expression vector, and transiently transfected into COS-7 cells. Conditioned media containing secreted apoF demonstrated CETP inhibitor activity, whereas cells transfected with vector alone did not. This CETP inhibitor activity was efficiently removed from the media by nickel-Sepharose, consistent with the 6-His tag incorporated into recombinant apoF. By Western blot, the 6-His-tagged protein had a molecular weight slightly larger than native apoF. The CETP inhibitor activity of recombinant apoF possessed the same LDL specificity, oleate sensitivity, and dependence on lipoprotein concentration as previously noted for LTIP. We conclude that LTIP and apoF are identical.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9880564     DOI: 10.1074/jbc.274.3.1814

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Conversion of lipid transfer inhibitor protein (apolipoprotein F) to its active form depends on LDL composition.

Authors:  Richard E Morton; Diane J Greene
Journal:  J Lipid Res       Date:  2011-09-21       Impact factor: 5.922

Review 2.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Apolipoprotein F: a natural inhibitor of cholesteryl ester transfer protein and a key regulator of lipoprotein metabolism.

Authors:  Yan Liu; Richard E Morton
Journal:  Curr Opin Lipidol       Date:  2020-08       Impact factor: 4.776

4.  High-Density Lipoprotein Proteomics: Identifying New Drug Targets and Biomarkers by Understanding Functionality.

Authors:  Scott Gordon; Anita Durairaj; Jason L Lu; W Sean Davidson
Journal:  Curr Cardiovasc Risk Rep       Date:  2010

Review 5.  Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond.

Authors:  Amy S Shah; Lirong Tan; Jason Lu Long; W Sean Davidson
Journal:  J Lipid Res       Date:  2013-02-24       Impact factor: 5.922

6.  Constitutive inhibition of plasma CETP by apolipoprotein C1 is blunted in dyslipidemic patients with coronary artery disease.

Authors:  Xavier Pillois; Thomas Gautier; Benjamin Bouillet; Jean-Paul Pais de Barros; Aline Jeannin; Bruno Vergès; Jacques Bonnet; Laurent Lagrost
Journal:  J Lipid Res       Date:  2012-04-02       Impact factor: 5.922

Review 7.  Speciated High-Density Lipoprotein Biogenesis and Functionality.

Authors:  C Rosales; W S Davidson; B K Gillard; A M Gotto; H J Pownall
Journal:  Curr Atheroscler Rep       Date:  2016-05       Impact factor: 5.113

8.  Apolipoprotein CI overexpression is not a relevant strategy to block cholesteryl ester transfer protein (CETP) activity in CETP transgenic mice.

Authors:  Thomas Gautier; David Masson; Miek C Jong; Jean-Paul Pais de Barros; Linda Duverneuil; Naig Le Guern; Valérie Deckert; Laure Dumont; Amandine Bataille; Zoulika Zak; Xian-Cheng Jiang; Louis M Havekes; Laurent Lagrost
Journal:  Biochem J       Date:  2005-01-01       Impact factor: 3.857

9.  Mechanism of inhibition defines CETP activity: a mathematical model for CETP in vitro.

Authors:  Laura K Potter; Dennis L Sprecher; Max C Walker; Frank L Tobin
Journal:  J Lipid Res       Date:  2009-03-11       Impact factor: 5.922

10.  Control of cholesteryl ester transfer protein activity by sequestration of lipid transfer inhibitor protein in an inactive complex.

Authors:  Yubin He; Diane J Greene; Michael Kinter; Richard E Morton
Journal:  J Lipid Res       Date:  2008-03-27       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.